Sleep Medicine
Volume 10, Issue 6 , Pages 604-610 , June 2009

The effects of pregabalin on sleep disturbance symptoms among individuals with fibromyalgia syndrome

  • I. Jon Russell

      Affiliations

    • University Clinical Research Center, University of Texas Health Science Center at San Antonio, 7703 Floyd Curl Dr., MC7868, San Antonio, TX 78229, USA
    • ,
  • Leslie J. Crofford

      Affiliations

    • Division of Rheumatology & Women’s Health, University of Kentucky, Room J-503 Kentucky Clinic, 740 S. Limestone, Lexington, KY 40536, USA
    • ,
  • Teresa Leon

      Affiliations

    • Pfizer Global Pharmaceuticals, 235 E. 42nd Street, New York, NY 10017, USA
    • ,
  • Joseph C. Cappelleri

      Affiliations

    • Pfizer Inc, Global Research and Development, 50 Pequot Avenue, New London, CT 06320, USA
    • ,
  • Andrew G. Bushmakin

      Affiliations

    • Pfizer Inc, Global Research and Development, 50 Pequot Avenue, New London, CT 06320, USA
    • ,
  • Ed Whalen

      Affiliations

    • Pfizer Global Pharmaceuticals, 235 E. 42nd Street, New York, NY 10017, USA
    • ,
  • Jeannette A. Barrett

      Affiliations

    • Pfizer Global Pharmaceuticals, 235 E. 42nd Street, New York, NY 10017, USA
    • ,
  • Alesia Sadosky

      Affiliations

    • Pfizer Inc, Global Outcomes Research, 235 East 42nd Street, New York, NY 10017, USA
    • Corresponding Author InformationCorresponding author. Tel.: +1 212 733 9491: fax: +1 646 441 4757.

Received 24 October 2008 ,Revised 23 January 2009 ,Accepted 31 January 2009.

References 

  1. Wolfe F, Smythe HA, Yunus MB, et al. The American College of Rheumatology 1990 Criteria for the classification of fibromyalgia. Report of the Multicenter Criteria Committee. Arthritis Rheum. 1990;33:160–172
  2. Wolfe F. The epidemiology of fibromyalgia. J Musculoskeletal Pain. 1993;1:137–148
  3. Wolfe F, Ross K, Anderson J, et al. The prevalence and characteristics of fibromyalgia in the general population. Arthritis Rheum. 1995;38:19–28
  4. Mease PJ, Arnold LM, Crofford LJ, et al. Identifying the clinical domains of fibromyalgia: contributions from clinician and patient delphi exercises. Arthritis Rheum. 2008;59:952–960
  5. Abad VC, Sarinas PSA, Guilleminault C. Sleep and rheumatologic disorders. Sleep Med Rev. 2008;12:211–228
  6. Moldofsky H, Alvarez-Horine S. Disordered sleep and sleep-related daytime functioning in fibromyalgia syndrome (FMS). Ann Rheum Dis. 2008;67(Suppl. II):256
  7. Edwards RR, Almeida DM, Klick B, et al. Duration of sleep contributes to next-day pain report in the general population. Pain. 2008;[Epub ahead of print]
  8. Moldofsky H, Scarisbrick P. Induction of neurasthenic musculoskeletal pain syndrome by selective sleep stage deprivation. Psychosom Med. 1976;38:35–44
  9. Moldofsky H, Scarisbrick P, England R, Smythe H. Musculosketal symptoms and non-REM sleep disturbance in patients with “fibrositis syndrome” and healthy subjects. Psychosom Med. 1975;37:341–351
  10. Affleck G, Urrows S, Tennen H, et al. Sequential daily relations of sleep, pain intensity, and attention to pain among women with fibromyalgia. Pain. 1996;68:363–368
  11. McKracken LM, Iverson GL. Disrupted sleep patterns and daily functioning in patients with chronic pain. Pain Res Manag. 2002;7:75–79
  12. Smith MT, Haythornthwaite JA. How do sleep disturbance and chronic pain inter-relate? Insights from the longitudinal and cognitive-behavioral clinical trials literature. Sleep Med Rev. 2004;8:119–132
  13. Bigatti SM, Hernandez AM, Cronan TA, Rand KL. Sleep disturbances in fibromyalgia syndrome: relationship to pain and depression. Arthritis Rheum. 2008;59:961–967
  14. Mease PJ, Russell IJ, Arnold LM, et al. A randomized, double-blind, placebo-controlled, phase III trial of pregabalin in the treatment of patients with fibromyalgia. J Rheumatol. 2008;35:502–514
  15. Arnold LM, Russell IJ, Diri EW, et al. A 14-week, randomized, double-blind, placebo-controlled monotherapy trial of pregabalin in patients with fibromyalgia. J Pain. 2008;[Epub ahead of print]
  16. Melzack R. The short-form McGill Pain Questionnaire. Pain. 1987;30:191–197
  17. Max MB. Neuropathic pain syndromes. In:  Max MB,  Portenoy R,  Laska E editor. Advances in pain research and management. vol. 18:New York: Raven Press Ltd.; 1991;p. 193–219
  18. Watson CPN. Neuropathic pain syndromes. In:  Max MB,  Portenoy R,  Laska E editor. Advances in pain research and management. vol. 18:New York: Raven Press Ltd.; 1991;p. 221–231
  19. Jensen MP, Karoly P. Self-report scales and procedures for assessing pain in adults. In:  Turk DC,  Melzack R editor. Handbook of pain assessment. New York: The Guildford Press; 1992;p. 135–151
  20. Hays R, Stewart A. Sleep measures. In:  Stewart A,  Ware J editor. Measuring functioning and well-being: the medical outcomes study approach. Durham, NC: Duke University Press; 1992;p. 235–259
  21. Hays RD, Martin SA, Sesti AM, Spritzer KL. Psychometric properties of the Medical Outcomes Study Sleep measure. Sleep Med. 2005;6:41–44
  22. Cappelleri JC, Bushmakin AG, McDermott AM, et al. Measurement properties of the Medical Outcomes Sleep Scale in patients with fibromyalgia. Sleep Med, in press, doi:10.1016/j.sleep.2008.09.004.
  23. Food and Drug Administration. Guidance for industry. Patient-reported outcome measures: use in medical product development to support labeling claims [Draft], <http://www.fda.gov/cder/guidance/5460dft.htm/>; 2006 [accessed 06.01.08].
  24. SAS Institute. SAS/STAT User’s Guide. Version 8. Cary, NC: SAS Institute; 2000.
  25. Cohen J. Statistical power analysis for the behavioral sciences. 2nd ed.. Hillsdale, NJ: Lawrence Erlbaum Associates; 1988;
  26. Hays RD, Farivar SS, Liu H. Approaches and recommendations for estimating minimally important differences for health-related quality of life measures. COPD. 2005;2:63–67
  27. Fitzmaurice G, Laird N, Ware J. Applied longitudinal analysis. New York: John Wiley & Sons; 2004;
  28. Kline R. Principles and practice of structural equation modeling. 2nd ed.. New York, NY: The Guilford Press; 2004;
  29. MacKinnon DP. Introduction to statistical mediation analysis. New York, NY: Taylor & Francis Group; 2008;
  30. Iacobucci D. Mediation analysis. Los Angeles, CA: Sage Publications; 2008;
  31. Muthén LK, Muthén BO. Mplus user’s guide. 4th ed.. Los Angeles, CA: Muthén & Muthén; 1998–2006;
  32. Bennett RM, Jones J, Turk DC, Matallana L. An internet survey of 2,596 people with fibromyalgia. BMC Musculoskelet Disord. 2007;8:27
  33. Farrara JT, Young JP, LaMoreauxb L, et al. Clinical importance of changes in chronic pain intensity measured on an 11-point numeric rating scale. Pain. 2001;94:149–158
  34. Jaeschke R, Singer J, Guyatt GH. Measurement of health status. Ascertaining the minimal clinically important difference. Control Clin Trials. 1989;10:407–415
  35. Kubota T, Fang J, Meltzer LT, Krueger JM. Pregabalin enhances nonrapid eye movement sleep. J Pharmacol Exp Ther. 2001;299:1095–1105
  36. Hindmarch I, Dawson J, Stanley N. A double-blind study in healthy volunteers to assess the effects on sleep of pregabalin compared with alprazolam and placebo. Sleep. 2005;28:187–193
  37. de Haas S, Otte A, de Weerd A, et al. Exploratory polysomnographic evaluation of pregabalin on sleep disturbance in patients with epilepsy. J Clin Sleep Med. 2007;3:473–478
  38. Moldofsky H. The significance, assessment, and management of nonrestorative sleep in fibromyalgia syndrome. CNS Spectr. 2008;13:22–26
  39. Rizzi M, Sarzi-Puttini P, Atzeni F, et al. Cyclic alternating pattern: a new marker of sleep alteration in patients with fibromyalgia?. J Rheumatol. 2004;31:1193–1199
  40. Burns JW, Crofford LJ, Chervin RD. Sleep stage dynamics in fibromyalgia patients and controls. Sleep Med. 2008;9:689–696
  41. Arnold L, Pritchett YL, D’Souza DN, et al. A randomized, double-blind, placebo-controlled trial of duloxetine in the treatment of women with fibromyalgia with or without major depressive disorder. Pain. 2005;119:5–15
  42. Arnold LM, Lu Y, Crofford LJ, et al. A double-blind, multicenter trial comparing duloxetine with placebo in the treatment of fibromyalgia patients with or without major depressive disorder. Arthritis Rheum. 2004;50:2974–2984
  43. Eichling PS, Sahni J. Menopause related sleep disorders. J Clin Sleep Med. 2005;1:291–300
  44. Annemans L, Wessely S, Spaepen E, et al. Health economic consequences related to the diagnosis of fibromyalgia syndrome. Arthritis Rheum. 2008;58:895–902
  45. Shah MA, Feinberg S, Krishnan E. Sleep-disordered breathing among women with fibromyalgia syndrome. J Clin Rheumatol. 2006;12:277–281
  46. Yunus MB, Aldag JC. Restless legs syndrome and leg cramps in fibromyalgia syndrome: a controlled study. BMJ. 1996;312:1339

PII: S1389-9457(09)00058-6

doi: 10.1016/j.sleep.2009.01.009

Sleep Medicine
Volume 10, Issue 6 , Pages 604-610 , June 2009

Article Tools

* Image Usage & Resolution